Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 25C-NBOH or None & onset: Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing)

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Leqembi (1)
classes:
Anti-amyloid beta (Aβ) monoclonal antibody (1) · targets protofibrils (1)
mechanism:
None (1)
uses:
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)
starting dose:
10 mg/kg IV every 2 weeks (1)
preparations:
200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1)
fda max:
10 mg/kg q2w (1)
routes:
IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1)
onset: (Click arrow to add another value)
duration:
Ongoing dosing (1)
halflife:
~5-7 days (1)
bioavailability:
100% (IV) (1)
pregnancy:
Limited data (1)
legal:
Rx; REMS-like program for ARIA monitoring (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"